Recent literature has explored incretin mimetics such as glucagon-like peptide-1 (GLP-1) receptor agonists, designed for T2DM and other insulin-resistant disorders, as adjunct therapy for patients with PCOS. This evidence concerns the gene GCG and type 2 diabetes mellitus.